Molecular diagnostics for monitoring and predicting therapeutic effect in cancer

Expert Review of Molecular Diagnostics

Volumn 11, Issue 1, 2011, Pages 9-12

  Cho, William Cs ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

cancer biomarker; circulating tumor cell; molecular diagnostics; predictive marker; therapeutic response

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; KI 67 ANTIGEN; MELAN A; MELANOMA ANTIGEN 3; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX3;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; METASTASIS; MOLECULAR DIAGNOSIS; REVIEW; TREATMENT RESPONSE;

HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM METASTASIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650561676     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.111     Document Type: Review

References (33)

1. Cho WC. Conquering cancer through discovery research. IUBMB Life 62(9), 655-659 (2010).
2. Cho WC. Cancer biomarkers (an overview). In: Methods of Cancer Diagnosis, Therapy and Prognosis (Volume 7). Hayat MA (Ed.). Springer, Berlin, Germany 21-40 (2010).
3. Goto Y, Koyanagi K, Narita N et al. Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. J. Invest. Dermatol. 130(1), 221-229 (2010).
4. Wang H, Yan H, Fu A et al. TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS ONE 5(8), e12051 (2010).
5. de Jong MC, Pramana J, van der Wal JE et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin. Cancer Res. 16(21), 5329-5338 (2010).
6. Daskalaki A, Agelaki S, Perraki M et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br. J. Cancer 101(4), 589-597 (2009).
7. Xenidis N, Ignatiadis M, Apostolaki S et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27(13), 2177-2184 (2009).
8. Bass MB, Sherman SI, Schlumberger MJ et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95(11), 5018-5027 (2010).
9. Koyanagi K, ODay SJ, Boasberg P et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin. Cancer Res. 16(8), 2402-2408 (2010).
10. Zuo Z, Jones D, Yao H et al. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod. Pathol. 23(11), 1524-1534 (2010).
11. Tabchy A, Valero V, Vidaurre T et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16(21) 5351-5361 (2010).
12. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 42(8), 1273-1281 (2010).
13. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim. Biophys. Acta 1805(2), 209-217 (2010).
14. Sarasin-Filipowicz M, Krol J, Markiewicz I et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15(1), 31-33 (2009).
15. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361(15), 1437-1447 (2009).
16. Aukema TS, Kappers I, Olmos RA et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J. Nucl. Med. 51(9), 1344-1348 (2010).
17. Decensi A, Guerrieri-Gonzaga A, Gandini S et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann. Oncol. DOI: 10.1093/ annonc/mdq427 (2010) (Epub ahead of print).
18. Woolston CM, Deen S, Al-Attar A et al. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Free Radic. Biol. Med. 49(8), 1263-1272 (2010).
19. Fusi A, Collette S, Busse A et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur. J. Cancer 45(18), 3189-3197 (2009).
20. Vitoux D, Mourah S, Kerob D et al. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases. Arch. Dermatol. 145(10), 1105-1113 (2009).
21. Goto Y, Arigami T, Murali R et al. High molecular weight-melanoma- associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res. 23(1), 137-140 (2010).
22. Hoffmann AC, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8), 628-636 (2010).
23. Koyanagi K, Bilchik AJ, Saha S et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin. Cancer Res. 14(22), 7391-7396 (2008).
24. Snchez-Espiridin B, Montalbn C, Lpez A et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116(8), e12-e17 (2010).
25. Cho WC. Role of miRNAs in lung cancer. Expert Rev. Mol. Diagn. 9(8), 773-776 (2009).
26. Cho WC. MicroRNAs as therapeutic targets for lung cancer. Expert Opin. Ther. Targets 14(10), 1005-1008 (2010).
27. Gallardo E, Navarro A, Violas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30(11), 1903-1909 (2009).
28. Cho WC (Ed.). An Omics Perspective on Cancer Research. Springer, Berlin, Germany (2010).
29. De Giorgi V, Pinzani P, Salvianti F et al. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J. Invest. Dermatol. 130(10), 2440-2447 (2010).
30. Kitago M, Koyanagi K, Nakamura T et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 55(4), 757-764 (2009).
31. Kojima T, Hashimoto Y, Watanabe Y et al. A simple biological imaging system for detecting viable human circulating tumor cells. J. Clin. Invest. 119(10), 3172-3181 (2009).
32. Bonnefoi H, Potti A, Delorenzi M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 8(12), 1071-1078 (2007).
33. Collingridge D. Expression of concern - Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: A substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 11(9), 813-814 (2010).